Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain
Conditions
Keywords
Collagen Crosslinking, Keratoconus, Dexamethasone, Intracanalicular Insert
Brief summary
There is no standard of care medication regimen for the management of pain and inflammation post-corneal crosslinking (CXL), although most cornea specialists agree on use of an antibiotic and steroid eye drop in the immediate postoperative period. However, steroid tapering schedule and use of additional topical non-steroidal anti-inflammatory (NSAID) eyedrops vary amongst practitioners. The goal of this study is to compare postoperative pain scores between patients receiving a tapering dose of topical steroids over 1-month post-CXL, versus those receiving an intracanalicular dexamethasone insert.
Detailed description
Keratoconus is a progressive ectatic disease of the cornea, leading to worsening of astigmatism and vision over time. With FDA approval of corneal collagen cross-linking (CXL), we now have the ability to halt the progression of keratoconus and prevent further vision loss in these patients. Although CXL has now become standard of care, the immediate post-operative period can be quite painful despite use of anti-inflammatory medications/eye drops. The goal of this study is to evaluate the efficacy of an intracanalicular dexamethasone insert in reduction of post-CXL pain as compared to routine steroid eye drop therapy. To date, no studies have been performed evaluating the success of an intracanalicular dexamethasone insert for the treatment of postoperative inflammation and pain in corneal cross-linking patients. Oftentimes, patients experience a great deal of discomfort post-CXL, which may also make it difficult to apply eye drops in the correct fashion. Use of a dexamethasone insert alleviates the need for postoperative steroid eye drops and may provide increased pain relief post-CXL as compared to topical therapy. This will be a head-to-head study where steroid therapy (topical or insert) will begin in a standard fashion on the date of CXL. This will allow for accurate comparison of a 4-week taper of topical steroids, versus a dexamethasone insert designed to release steroid for 30 days.
Interventions
DRUGDextenza
Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain
DRUGPrednisolone Acetate
post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
Sponsors
Ocular Therapeutix, Inc.
Sight Medical Doctors PLLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Two cohorts of patients will be studied (10 patients each group). Cohort A: intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or another class if allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye 4 times daily x 10 days). Cohort B: Patients are placed on standard postoperative regimen of postoperative fluoroquinolone antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye 4 times daily (QID) x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: 4 times daily x1 week, three times daily (TID) x 1 week, twice daily (BID) x 1 week, and once daily (QD) x 1 week).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Progressive keratoconus with planned corneal cross-linking in one or both eyes * Age 18 years and older * Ability to provide informed consent for procedures * Ability to attend scheduled follow up visits
Exclusion criteria
* Age less than 18 * Pregnancy/currently breast-feeding * Inability to provide informed consent * Documented adverse reaction to steroid (e.g. steroid responder, allergy, etc) * Punctal stenosis * Previous corneal transplant surgery * Systemic concomitant use of controlled substance for pain management (i.e. oxycodone) * Concurrent use of topical steroid eye drops * Systemic, topical or intravitreal steroid use within 1 month of baseline * Active history of chronic or recurrent inflammatory eye disease in either eye * History of ocular herpetic infection (inclusive of Herpes Simplex 1/2, Varicella Zoster, Epstein Barr, Cytomegalovirus) * History of neurotrophic keratitis, uncontrolled diabetes, or other disease entities that may preclude proper healing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Assessed at 1 day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total) | Utilizing the standardized Wong-Baker visual analog pain scale, graded from 0 to 10 (no pain to increasingly worse pain (worst at 10/10)) |
| Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | assessed at day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total) | Assessment of corneal edema/cells (if any), degree of conjunctiva injection (if any) Grading will be from 0 to 4, with 0 being no conjunctival injection, and 4 indicating severe, diffuse conjunctival injection. Presence of corneal cells will be noted if present or absent. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Corneal Re-epithelialization | Assessed at 1 day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total) | Evaluation of rate of corneal re-epithelialization post-crosslinking at 1 day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 |
| Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | postoperative week 4 (POW4) | Questionnaire at final visit regarding ease of postoperative eye drop use |
| Notation of Need for Use of Rescue Pain Medication | Assessement of use of additional/adjunctive pain/antiinflammatory medications will be done for each patient at postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total) | Use of oral non-steroidal anti-inflammatory (NSAID), acetaminophen, prescribed pain medication) between groups |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Group A Intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days).
Dextenza: Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain | 10 |
| Group B Patients are placed on standard postoperative regimen of postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: QID x1 week, TID x 1 week, BID x 1 week, and Qday x 1 week.
Prednisolone Acetate: post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month | 10 |
| Total | 20 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 1 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Group B | Total | Group A |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants | 20 Participants | 10 Participants |
| Age, Continuous | 36.3 years STANDARD_DEVIATION 10.29 | 31.15 years STANDARD_DEVIATION 5.15 | 26 years STANDARD_DEVIATION 3.89 |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Region of Enrollment United States | 10 participants | 20 participants | 10 participants |
| Sex: Female, Male Female | 4 Participants | 10 Participants | 6 Participants |
| Sex: Female, Male Male | 6 Participants | 10 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 10 |
| other Total, other adverse events | 0 / 8 | 0 / 10 |
| serious Total, serious adverse events | 0 / 8 | 0 / 10 |
Outcome results
Primary
Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4)
Utilizing the standardized Wong-Baker visual analog pain scale, graded from 0 to 10 (no pain to increasingly worse pain (worst at 10/10))
Time frame: Assessed at 1 day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total)
Population: By POD7, no patient complained of pain or discomfort (i.e, pain scale rating was 0).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Group A | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative day 3 | 0.2 score on a scale from 0 - 10 | Standard Deviation 0.4 |
| Group A | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative week 2 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
| Group A | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative day 1 | 1.3 score on a scale from 0 - 10 | Standard Deviation 0.45 |
| Group A | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative week 3 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
| Group A | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative day 7 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
| Group A | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative week 4 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
| Group A | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative day 0 | 6.4 score on a scale from 0 - 10 | Standard Deviation 1.3 |
| Group B | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative week 4 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
| Group B | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative day 0 | 6.6 score on a scale from 0 - 10 | Standard Deviation 1.62 |
| Group B | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative day 1 | 2 score on a scale from 0 - 10 | Standard Deviation 1.18 |
| Group B | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative day 3 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
| Group B | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative day 7 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
| Group B | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative week 2 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
| Group B | Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | Postoperative week 3 | 0 score on a scale from 0 - 10 | Standard Deviation 0 |
Primary
Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4)
Assessment of corneal edema/cells (if any), degree of conjunctiva injection (if any) Grading will be from 0 to 4, with 0 being no conjunctival injection, and 4 indicating severe, diffuse conjunctival injection. Presence of corneal cells will be noted if present or absent.
Time frame: assessed at day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Group A | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative day 1 | 0.5 score on a scale 0-4 | Standard Deviation 0 |
| Group A | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative week 2 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group A | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative day 3 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group A | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative week 3 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group A | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | date of surgery | 0.5 score on a scale 0-4 | Standard Deviation 0 |
| Group A | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative week 4 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group A | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative day 7 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group B | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative week 4 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group B | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative day 1 | 0.5 score on a scale 0-4 | Standard Deviation 0 |
| Group B | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative day 3 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group B | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative day 7 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group B | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative week 2 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group B | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | postoperative week 3 | 0 score on a scale 0-4 | Standard Deviation 0 |
| Group B | Degree and Improvement of Ocular Surface Inflammation Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3 and 4) | date of surgery | 0.5 score on a scale 0-4 | Standard Deviation 0 |
Secondary
Notation of Need for Use of Rescue Pain Medication
Use of oral non-steroidal anti-inflammatory (NSAID), acetaminophen, prescribed pain medication) between groups
Time frame: Assessement of use of additional/adjunctive pain/antiinflammatory medications will be done for each patient at postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total)
Population: Number of patients using rescue pain medication were assessed from operative day (POD0) through POW4.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group A | Notation of Need for Use of Rescue Pain Medication | POD 3 use of pain medication | 0 Participants |
| Group A | Notation of Need for Use of Rescue Pain Medication | POW2 use of pain medication | 0 Participants |
| Group A | Notation of Need for Use of Rescue Pain Medication | POD 1 use of pain medication | 1 Participants |
| Group A | Notation of Need for Use of Rescue Pain Medication | POW3 use of pain medication | 0 Participants |
| Group A | Notation of Need for Use of Rescue Pain Medication | POD 7 use of pain medication | 0 Participants |
| Group A | Notation of Need for Use of Rescue Pain Medication | POW4 use of pain medication | 0 Participants |
| Group A | Notation of Need for Use of Rescue Pain Medication | POD 0 use of pain medication | 6 Participants |
| Group B | Notation of Need for Use of Rescue Pain Medication | POW4 use of pain medication | 0 Participants |
| Group B | Notation of Need for Use of Rescue Pain Medication | POD 0 use of pain medication | 6 Participants |
| Group B | Notation of Need for Use of Rescue Pain Medication | POD 1 use of pain medication | 1 Participants |
| Group B | Notation of Need for Use of Rescue Pain Medication | POD 3 use of pain medication | 0 Participants |
| Group B | Notation of Need for Use of Rescue Pain Medication | POD 7 use of pain medication | 0 Participants |
| Group B | Notation of Need for Use of Rescue Pain Medication | POW2 use of pain medication | 0 Participants |
| Group B | Notation of Need for Use of Rescue Pain Medication | POW3 use of pain medication | 0 Participants |
Secondary
Rate of Corneal Re-epithelialization
Evaluation of rate of corneal re-epithelialization post-crosslinking at 1 day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4
Time frame: Assessed at 1 day of surgery, postoperative days 1 ,3, 7, postoperative weeks 2 ,3 and 4 (7 visits total)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Group A | Rate of Corneal Re-epithelialization | Postoperative week 4 | 0 percentage epithelial defect | Standard Deviation 0 |
| Group A | Rate of Corneal Re-epithelialization | Day of surgery | 100 percentage epithelial defect | Standard Deviation 0 |
| Group A | Rate of Corneal Re-epithelialization | Postoperative day 1 | 37.75 percentage epithelial defect | Standard Deviation 5.35 |
| Group A | Rate of Corneal Re-epithelialization | Postoperative day 3 | 7.85 percentage epithelial defect | Standard Deviation 2.47 |
| Group A | Rate of Corneal Re-epithelialization | Postoperative day 7 | 0 percentage epithelial defect | Standard Deviation 0 |
| Group A | Rate of Corneal Re-epithelialization | postoperative week 2 | 0 percentage epithelial defect | Standard Deviation 0 |
| Group A | Rate of Corneal Re-epithelialization | Postoperative week 3 | 0 percentage epithelial defect | Standard Deviation 0 |
| Group B | Rate of Corneal Re-epithelialization | Postoperative week 4 | 0 percentage epithelial defect | Standard Deviation 0 |
| Group B | Rate of Corneal Re-epithelialization | Postoperative day 7 | 0 percentage epithelial defect | Standard Deviation 0 |
| Group B | Rate of Corneal Re-epithelialization | Day of surgery | 100 percentage epithelial defect | Standard Deviation 0 |
| Group B | Rate of Corneal Re-epithelialization | Postoperative week 3 | 0 percentage epithelial defect | Standard Deviation 0 |
| Group B | Rate of Corneal Re-epithelialization | Postoperative day 1 | 34.75 percentage epithelial defect | Standard Deviation 7.15 |
| Group B | Rate of Corneal Re-epithelialization | postoperative week 2 | 0 percentage epithelial defect | Standard Deviation 0 |
| Group B | Rate of Corneal Re-epithelialization | Postoperative day 3 | 6 percentage epithelial defect | Standard Deviation 2 |
Secondary
Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert
Questionnaire at final visit regarding ease of postoperative eye drop use
Time frame: postoperative week 4 (POW4)
Population: Patients completed an ease-of-use questionnaire regarding postoperative eye drops.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Group A | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q1. Were directions regarding eyedrop use post-CXL easy to follow? | yes to Question | 8 Participants |
| Group A | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q3. Was it difficult to remember to use postoperative eye drops? | no to Question | 8 Participants |
| Group A | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q1. Were directions regarding eyedrop use post-CXL easy to follow? | no to Question | 0 Participants |
| Group A | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q2. Was it cumbersome to use eyedrops for more than 10 days? | yes to Question | 0 Participants |
| Group A | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q2. Was it cumbersome to use eyedrops for more than 10 days? | no to Question | 8 Participants |
| Group A | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q3. Was it difficult to remember to use postoperative eye drops? | yes to Question | 0 Participants |
| Group B | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q2. Was it cumbersome to use eyedrops for more than 10 days? | no to Question | 10 Participants |
| Group B | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q2. Was it cumbersome to use eyedrops for more than 10 days? | yes to Question | 0 Participants |
| Group B | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q3. Was it difficult to remember to use postoperative eye drops? | no to Question | 10 Participants |
| Group B | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q1. Were directions regarding eyedrop use post-CXL easy to follow? | yes to Question | 10 Participants |
| Group B | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q3. Was it difficult to remember to use postoperative eye drops? | yes to Question | 0 Participants |
| Group B | Subjective 'Ease of Postoperative Care' for Patients Receiving Standard Topical Steroid Eye Drop Taper vs. Dexamethasone Insert | Q1. Were directions regarding eyedrop use post-CXL easy to follow? | no to Question | 0 Participants |